Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Cue Biopharma
Milton S. Hershey Medical Center
Assistance Publique - Hôpitaux de Paris
Memorial Sloan Kettering Cancer Center
University Hospital, Antwerp